King Fahd University of Petroleum and Minerals

Christophe Tratrat

Michelyne Haroun

Katharigatta N Venugopala

Mohamed A Morsy

Sandeep Chandrashekharappa

Mahesh Attimarad

Anroop B Nair

Nagaraja Sreeharsha

Sheena Shashikanth

Pran Kishore Deb

Bandar Aldhubiab

Melendran Pillay

Vijaykumar Uppar

Basavaraj Padmashali

Bandar Adlhubiab

Pyrimido[4,5-b]indole compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrimido[4,5-b]indole compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases. The pyrimido[4,5-b]indole compounds include compounds of the general formula:

Substituted pyrimido[4,5-b]indoles as CK2 inhibitors

Novel 7H-pyrido[4',3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

7H-pyrido[4',3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors

Novel pyrazino[1′,2′:1,5]pyrazolo[4,3-c][1,6]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazino[1′,2′:1,5]pyrazolo[4,3-c][1,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases. The pyrazino[1′,2′:1,5]pyrazolo[4,3-c][1,6]naphthyridine compounds have the following general formula:

Substituted pyrazino[1',2′:1,5]pyrazolo[4,3-c][1,6]naphthyridines as CK2 inhibitors

Novel pyrrolo[3,2-c]isoquinoline-2,3-diones, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c]isoquinoline-2,3-dione compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrrolo[3,2-c]isoquinoline-2,3-dione compounds as CK2 inhibitors

Novel pyrido[3',4′:4,5]pyrrolo[3,2-c]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3′,4′:4,5]pyrrolo[3,2-c]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrido[3',4′:4,5]pyrrolo[3,2-c]naphthyridine compounds as CK2 inhibitors

Novel pyrazino[1',2′:1,5]pyrazolo[4,3-c][2,6]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazino[1′,2′:1,5]pyrazolo[4,3-c][2,6]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrazino[1',2′:1,5]pyrazolo[4,3-c] [2,6] naphthyridine compounds as CK2 inhibitors

Novel pyrimido[1',6′: 1,5]pyrazolo[4,3-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrimido[1′,6′: 1,5]pyrazolo[4,3-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrimido[1',6′: 1,5]pyrazolo[4,3-c] [2,7] naphthyridines as CK2 inhibitors

Novel imidazo[1,5-a]pyrido[4,3-e]pyrazine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The imidazo[1,5-a]pyrido[4,3-e]pyrazine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Imidazo[1,5-a]pyrido[4,3-e]pyrazines as CK2 inhibitors

Novel pyrazolo[1,5-c]pyrido[3,4-e]pyrimidine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrazolo[1,5-c]pyrido[3,4-e]pyrimidine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrazolo[1,5-c]pyrido[3,4-e]pyrimidines as CK2 inhibitors

Novel pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrrolo[3,2-c][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors

Pyrimido[4,5-b]indole compounds, having the formula: Please replace the originally-filed Specification with the Substitute Specification submitted herewith. Both a “corrected” copy of the Specification and a “clean” copy of the Substitute Specification are attached hereto. No new subject matter has been incorporated herein.

Novel pyrido[3,4-e][1,2,4]triazolo[4,3-c]pyrimidine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3,4-e][1,2,4]triazolo[4,3-c]pyrimidine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrido[3,4-e][1,2,4]triazolo[4,3-c]pyrimidines as CK2 inhibitors

Novel pyrimido[1',6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrimido[1′,6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Pyrimido[1',6′:1,5]pyrazolo[4,3-b][1,7]naphthyridine compounds as CK2 inhibitors

Pyrrolo[3,2-C][2,6]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors

Novel pyrido[4',3′:4,5]pyrrolo[2,3-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[4′,3′:4,5]pyrrolo[2,3-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.

Growing community of inventors

Al-Ahsa, Saudi Arabia

Christophe Tratrat